| 查看: 709 | 回复: 0 | ||
caijing1986铜虫 (初入文坛)
|
[求助]
专业翻译英文摘要
|
|
Standard Versus Extended Duration DirectActing Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment Abstract Background: Response-guided hepatitis C therapy was standard with interferon-based regimens but is not used for direct-acting antivirals (DAAs). Week 4 viral kinetics may predict sustained virological response (SVR) with DAAs, but it is unclear whether extending therapy in slow responders affects outcomes. Objectives: The primary objective was to compare SVR rates between traditional and extended duration groups. Secondary objectives were to compare SVR rates among subgroups and to determine factors associated with SVR. Methods: This institutional review board–approved, retrospective, single-center study identified patients with chronic hepatitis C virus (HCV) infection with detectable week 4 HCV RNA who were treated with DAAs. Patients were excluded for early discontinuation, treatment regimen not recommended first-line, or missing HCV RNA labs. Patients were stratified into traditional and extended duration groups. The primary end point was SVR. Secondary end points included factors associated with SVR and rationale for extension of therapy duration. Results: A total of 363 patients were included; 58 (16%) received extended therapy. Patients were primarily genotype 1a (70%) and treatment naïve (80%). More than half had advanced fibrosis or cirrhosis. SVR12 rates were 100% in the extended duration group and 96.7% in the traditional duration group (P = 0.37). There were no associations with SVR and prespecified patient-specific factors. Sample size was limited. Conclusion and Relevance:Based on these findings, a recommendation for extension of therapy cannot be made for patients with detectable HCV RNA at week 4 of treatment at this time. Cost analyses may help guide recommendations to re-treat rare failures versus extend therapy in all slow responders. Keywords hepatitis C, response-guided therapy, direct-acting antivirals |
回复此楼» 猜你喜欢
跳槽后在研项目怎么办？
已经有5人回复
-
93BebMhtakh前后11位开头都是大写
已经有6人回复
-
什么时候开奖？
已经有8人回复
-
只有每年这种时候来逛逛小木虫
已经有26人回复
-
2026国自然函评费到账
已经有10人回复
-
filecode，4个jtjc了
已经有16人回复
-
售一区SCI文章T0P，我:8O.551.O54,科目全,可十急
已经有4人回复
-
人气不行了
已经有8人回复
-
今天基金会出结果吗？20260819
已经有17人回复
-
售SCI一区T0P文章，我:8O.55.1.O.54,科目全,可伽急
已经有9人回复
40